论文部分内容阅读
目的:分组比较传统CAV方案(环磷酰胺+阿霉素+长春新硷)和金喜素和顺铂方案对小细胞肺癌患者的治疗效果。方法:通过分组对比分析164例小细胞肺癌患者连续三次应用传统CAV(环磷酰胺、阿霉素、长春新硷)方案和连续三次应用金喜素联合顺铂方案化疗,检测肿块横径与直径缩小程度,比较两个方案对小细胞肺癌的治疗作用。结果:金喜素联合顺铂方案时小细胞肺癌总有效率迭56．5％,传统CAV方案总有效率41．8％,两组比较有明显统计学意义(x2=18．4>16．27,v=3,p<0．001),两组毒副反应比较无统计学意义(x2=5．62<9．49,v=4,p>0．05)。结论:金喜素联合顺铂方案时小细胞肺癌较传统CAV方案有更明显的疗效,值得临床应用。
OBJECTIVE: To compare the curative effect of traditional CAV regimen (cyclophosphamide + doxorubicin + vincristine) and gold and cisplatin regimen in patients with small cell lung cancer. Methods: 164 cases of small cell lung cancer patients were treated by traditional CAV (cyclophosphamide, doxorubicin, vincristine) three times in a row and three times consecutively with chemotherapy combined with cisplatin in 164 cases of small cell lung cancer by grouping. The diameter and diameter of tumor were measured , Compared the two programs on the treatment of small cell lung cancer. Results: The total effective rate of small cell lung cancer was 56.5% and the total effective rate of traditional CAV was 41.8%. The two groups had significant statistical significance (x2 = 18.4> 16.27, v = 3, p <0.001). There was no significant difference in the side effects between the two groups (x2 = 5.62 <9.49, v = 4, p> 0.05). CONCLUSION: Small-cell lung cancer is more effective than the traditional CAV regimen in the combination of gold and cisplatin, which is worthy of clinical application.